UroGen Pharma Ltd. (URGN) stock analysis

URGN · UroGen Pharma Ltd.

Latest recorded price: USD 28.10

Sector and industry: Healthcare · Biotechnology

Fiscal 2025 figures: revenue growth 19.5%, free cash flow margin -148.2%, ROIC -2,450.1%. The model flags 1 risk signal for this company (1 high severity).

Similar companies in Healthcare